Literature DB >> 21123864

Recommended guidelines for submission, trimming, margin evaluation, and reporting of tumor biopsy specimens in veterinary surgical pathology.

D A Kamstock1, E J Ehrhart, D M Getzy, N J Bacon, K M Rassnick, S D Moroff, S M Liu, R C Straw, C A McKnight, R L Amorim, D Bienzle, G D Cassali, J M Cullen, M M Dennis, D G Esplin, R A Foster, M H Goldschmidt, A D Gruber, E Hellmén, E W Howerth, P Labelle, S D Lenz, T P Lipscomb, E Locke, L D McGill, M A Miller, P J Mouser, D O'Toole, R R Pool, B E Powers, J A Ramos-Vara, P Roccabianca, A D Ross, A Sailasuta, G Sarli, T J Scase, F Y Schulman, A M Shoieb, K Singh, D Sledge, R C Smedley, K C Smith, W L Spangler, B Steficek, P C Stromberg, V E Valli, J Yager, M Kiupel.   

Abstract

Neoplastic diseases are typically diagnosed by biopsy and histopathological evaluation. The pathology report is key in determining prognosis, therapeutic decisions, and overall case management and therefore requires diagnostic accuracy, completeness, and clarity. Successful management relies on collaboration between clinical veterinarians, oncologists, and pathologists. To date there has been no standardized approach or guideline for the submission, trimming, margin evaluation, or reporting of neoplastic biopsy specimens in veterinary medicine. To address this issue, a committee consisting of veterinary pathologists and oncologists was established under the auspices of the American College of Veterinary Pathologists Oncology Committee. These consensus guidelines were subsequently reviewed and endorsed by a large international group of veterinary pathologists. These recommended guidelines are not mandated but rather exist to help clinicians and veterinary pathologists optimally handle neoplastic biopsy samples. Many of these guidelines represent the collective experience of the committee members and consensus group when assessing neoplastic lesions from veterinary patients but have not met the rigors of definitive scientific study and investigation. These questions of technique, analysis, and evaluation should be put through formal scrutiny in rigorous clinical studies in the near future so that more definitive guidelines can be derived.

Entities:  

Mesh:

Year:  2010        PMID: 21123864     DOI: 10.1177/0300985810389316

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  14 in total

1.  Intra-operative imaging of surgical margins of canine soft tissue sarcoma using optical coherence tomography.

Authors:  Laura E Selmic; Jonathan Samuelson; Jennifer K Reagan; Kelly J Mesa; Elizabeth Driskell; Joanne Li; Marina Marjanovic; Stephen A Boppart
Journal:  Vet Comp Oncol       Date:  2018-11-13       Impact factor: 2.613

Review 2.  Treatment of Canine Oral Melanomas: A Critical Review of the Literature.

Authors:  Paolo Pazzi; Gerhard Steenkamp; Anouska J Rixon
Journal:  Vet Sci       Date:  2022-04-19

3.  Prognostic impact of bone invasion in canine oral malignant melanoma treated by surgery and anti-CSPG4 vaccination: A retrospective study on 68 cases (2010-2020).

Authors:  Mariateresa Camerino; Davide Giacobino; Luca Manassero; Selina Iussich; Federica Riccardo; Federica Cavallo; Lidia Tarone; Matteo Olimpo; Elena Lardone; Marina Martano; Sara Del Magno; Paolo Buracco; Emanuela Morello
Journal:  Vet Comp Oncol       Date:  2021-09-06       Impact factor: 2.385

4.  Diagnostic accuracy of optical coherence tomography for surgical margin assessment of feline injection-site sarcoma.

Authors:  Mary J Coleman; Laura E Selmic; Jonathan P Samuelson; Ryan Jennings; Pin-Chieh Huang; Eric M McLaughlin; Vincent A Wavreille; Josephine A Dornbusch; Janis Lapsley; James Howard; Edward Cheng; Alex Kalamaras; Kendra Hearon; Megan Cray; Janet Grimes; Brandan Wustefeld-Janssens; Katie Kennedy; Owen Skinner; Pierre Amsellem; Stephen A Boppart
Journal:  Vet Comp Oncol       Date:  2021-09-14       Impact factor: 2.613

5.  Transcriptome Analysis of Canine Cutaneous Melanoma and Melanocytoma Reveals a Modulation of Genes Regulating Extracellular Matrix Metabolism and Cell Cycle.

Authors:  Chiara Brachelente; Katia Cappelli; Stefano Capomaccio; Ilaria Porcellato; Serenella Silvestri; Laura Bongiovanni; Raffaella De Maria; Andrea Verini Supplizi; Luca Mechelli; Monica Sforna
Journal:  Sci Rep       Date:  2017-07-25       Impact factor: 4.379

6.  Evaluation of information presented within mast cell tumour histopathology reports in the United States: 2012-2015.

Authors:  Jennifer K Reagan; Laura E Selmic; Caroline Fallon; Elizabeth A Driskell; Laura D Garrett
Journal:  Vet Med Sci       Date:  2018-06-07

7.  Preliminary safety and imaging efficacy of the near-infrared fluorescent contrast agent DA364 during fluorescence-guided surgery in dogs with spontaneous superficial tumors.

Authors:  Sophie Favril; Chiara Brioschi; Francesco Blasi; Hilde de Rooster; Katrien Vanderperren; Eline Abma; Emmelie Stock; Nausikaa Devriendt; Ingeborgh Polis; Hilde De Cock; Alessia Cordaro; Luigi Miragoli; Paolo Oliva; Giovanni Valbusa; Charline Alleaume; Isabelle Tardy; Alessandro Maiocchi; Fabio Tedoldi
Journal:  Oncotarget       Date:  2020-06-16

8.  Bilateral thyroid adenomas in an alpaca.

Authors:  Kate Burbery; Olivier Simon; Lucy Woolford; Gustavo Ferlini Agne
Journal:  J Vet Intern Med       Date:  2021-10-09       Impact factor: 3.333

9.  Evaluating optical coherence tomography for surgical margin assessment of canine mammary tumours.

Authors:  Carolina Fabelo; Laura E Selmic; Pin-Cheh Huang; Jonathan P Samuelson; Jennifer K Reagan; Alexandra Kalamaras; Vincent Wavreille; Guillermo L Monroy; Marina Marjanovic; Stephen A Boppart
Journal:  Vet Comp Oncol       Date:  2020-07-26       Impact factor: 2.613

10.  miRNA profiles of canine cutaneous mast cell tumours with early nodal metastasis and evaluation as potential biomarkers.

Authors:  Valentina Zamarian; Roberta Ferrari; Damiano Stefanello; Fabrizio Ceciliani; Valeria Grieco; Giulietta Minozzi; Lavinia Elena Chiti; Maddalena Arigoni; Raffaele Calogero; Cristina Lecchi
Journal:  Sci Rep       Date:  2020-11-03       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.